Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer

Clinical Cancer Research

Volumn 16, Issue 21, 2010, Pages 5351-5361

  Tabchy, Adel ^a   Valero, Vicente ^a   Vidaurre, Tatiana ^c   Lluch, Ana ^d   Gomez, Henry ^c   Martin, Miguel ^d   Qi, Yuan ^a   Barajas Figueroa, Luis Javier ^e   Souchon, Eduardo ^b   Coutant, Charles ^a   Doimi, Franco D ^c   Ibrahim, Nuhad K ^a   Gong, Yun ^a   Hortobagyi, Gabriel N ^a   Hess, Kenneth R ^a   Symmans, W Fraser ^a   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^d Grupo Español de Investigación en Cáncer de Mama   (Spain)

^e INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEEDLE BIOPSY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78049466887     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1265     Document Type: Article

References (21)

1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85. (Pubitemid 28363030)
2. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
3. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
4. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
5. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005;23:7265-77.
6. Andre F, Mazouni C, Liedtke C, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 2008;108:183-90.
7. Liedtke C, Hatzis C, Symmans WF, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009;27:3185-91.
8. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplification and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin or fluorouracil: Danish Breast Cancer cooperative Group. J Clin Oncol 2005;23:7483-90.
9. Rouzier R, Rajan R, Hess KR, et al. Microtubule associated protein ⊤ is a predictive marker and modulator of response to paclitaxel-containing preoperative chemotherapy in breast cancer. Proc Natl Acad Sci U S A 2005;102:8315-20.
10. Esteva FJ, Hortobagyi GN. Topoisomerase IIα amplification and anthracycline-based chemotherapy: the jury is still out. J Clin Oncol 2009;27:3416-7.
11. Pusztai L, Jeong JH, Gong Y, et al. Evaluation of microtubule-associated protein-⊤ expression as a prognostic and predictive marker in NSABP-B 28 randomized clinical trial. J Clin Oncol 2009;27:4287-92.
12. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol 2007;18:xii15-20.
13. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-44.
14. Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005;23:8331-9.
15. Mazouni C, Peintinger F, Kau SW, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007;25:2650-5.
16. Symmans WF, Ayers M, Clark EA, et al. Total RNA yield and microarray gene expression profiles from fine needle aspiration and core needle biopsy samples of breast cancer. Cancer 2003;97:2960-71.
17. Peintinger F, Anderson K, Mazouni C, et al. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy breast cancer. Clin Cancer Res 2007;13:4078-82.
18. Pounds S, Morris SW. Estimating the occurrence of false positive and false negatives in microarray studies by approximating and partitioning the empirical distribution of P-values. Bioinformatics 2003;19:1236-42.
19. Sotiriou C, Pusztai L. Gene expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
20. Hatzis C, Symmans WF, Lin F, et al. Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers [abstract 571]. Proc Am Soc Clin Oncol 2008;26:23s.
21. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-92.